TY  - CHAP
M1  - Book, Section
TI  - Endocrine Pancreas and Pharmacotherapy of Diabetes Mellitus and Hypoglycemia
A1  - Powers, Alvin C.
A1  - D’Alessio, David
A2  - Brunton, Laurence L.
A2  - Knollmann, Björn C.
PY  - 2023
T2  - Goodman & Gilman's: The Pharmacological Basis of Therapeutics, 14th Edition
AB  - Diabetes  mellitus  is  a  heterogeneous  spectrum  of  metabolic  disorders,  likely  arising  from  disparate  genetic  and  environmental  factors,  with  a  common  outcome  of  impaired  glucose  homeostasis  and  hyperglycemia.  The  pathogenesis,  for  most  persons,  involves  some  combination  of  insufficient  insulin  secretion,  reduced  responsiveness  to  endogenous  or  exogenous  insulin,  increased  glucose  production,  and  abnormalities  in  fat  and  protein  metabolism.  The  resulting  hyperglycemia  may  lead  to  both  acute  symptoms  and  metabolic  abnormalities.  A  major  source  of  the  morbidity  of  diabetes  is  chronic  end-organ  damage  that  arises  from  prolonged  hyperglycemia  and  includes  retinopathy,  neuropathy,  nephropathy,  and  cardiovascular  disease.  These  chronic  complications  can  be  mitigated  in  many  patients  by  sustained  control  of  the  blood  glucose  and  treatment  of  comorbidities  such  as  hypertension  and  dyslipidemia  (Nathan  and  DCCT/EDIC  Research  Group,  2013).  A  wide  variety  of  treatment  options  for  hyperglycemia  that  target  different  processes  involved  in  glucose  regulation  or  dysregulation  are  available  (ADA,  2022c).  
SN  - 
PB  - McGraw-Hill Education
CY  - New York, NY
Y2  - 2024/04/16
UR  - hemonc.mhmedical.com/content.aspx?aid=1193237554
ER  -